Clinical Trial Update: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid [Phase 3]

View source ↗

Summary

A Phase 3 study in adults with asthma on medium or high-dose inhaled corticosteroids compared the superiority of CHF 1535 pMDI 800/24µg total daily dose versus …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF 1535 pMDI 800/24µg total daily dose
• CHF 718 pMDI 800µg total daily dose

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2025-09-04